These results suggested that in normal karyotype AML patients without FLT3-ITD, NPM1 mutations conferred survival benefits only when IDH mutations were present simultaneously.327 The conflicting results of these studies required further investigation. The gene discussed is FLT3; the disease is acute myeloid leukemia.